Protease-activated receptor-2 modulates protease-activated receptor-1-driven neointimal hyperplasia

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 12, 2011, Pages

  Sevigny, Leila M ^a,b   Austin, Karyn M ^a,b   Zhang, Ping ^a   Kasuda, Shogo ^a   Koukos, Georgios ^a   Sharifi, Sheida ^c   Covic, Lidija ^a,b   Kuliopulos, Athan ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT AUBURN HOSPITAL   (United States)

Author keywords

carotid arteries; receptors; restenosis; thrombin; vascular muscle

Indexed keywords

CALCIUM; CHEMICAL AGENT; P1PAL 13; P1PAL 7; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CALCIUM MOBILIZATION; CAROTID ARTERY; CAROTID ARTERY LIGATION; CELL ACTIVITY; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; FEMALE; HISTOPATHOLOGY; MITOCHONDRION; MITOGENESIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER;

ANIMALS; CAROTID ARTERIES; CELL PROLIFERATION; FEMALE; HYPERPLASIA; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; MUSCLE, SMOOTH, VASCULAR; NEOINTIMA; PHENOTYPE; RECEPTOR, PAR-1; RECEPTOR, PAR-2;

EID: 81755184108     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.238261     Document Type: Article

References (42)

1. Orford JL, Selwyn AP, Ganz P, Popma JJ, Rogers C. The comparative pathobiology of atherosclerosis and restenosis. Am J Cardiol. 2000;86: 6H-11H.
2. Douglas JS Jr. Pharmacologic approaches to restenosis prevention. Am J Cardiol. 2007;100:10K-16K.
3. Sukhija R, Mehta JL, Sachdeva R. Present status of coronary bifurcation stenting. Clin Cardiol. 2008;31:63-66. (Pubitemid 351317214)
4. Leger AJ, Covic L, Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation. 2006;114:1070-1077. (Pubitemid 44358884)
5. O'Brien PJ, Molino M, Kahn M, Brass LF. Protease activated receptors: theme and variations. Oncogene. 2001;20:1570-1581. (Pubitemid 32336845)
6. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64:1057-1068. (Pubitemid 121001193)
7. Kuliopulos A, Covic L, Seeley SK, Sheridan PJ, Helin J, Costello CE. Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy. Biochemistry. 1999;38:4572-4585.
8. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell. 2005;120:303-313. (Pubitemid 40222426)
9. Trivedi V, Boire A, Tchernychev B, Kaneider NC, Leger AJ, O'Callaghan K, Covic L, Kuliopulos A. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell. 2009;137:332-343.
10. Ossovskaya VS, Bunnett NW. Protease-activated receptors: contribution to physiology and disease. Physiol Rev. 2004;84:579-621. (Pubitemid 38365493)
11. Seitz I, Hess S, Schulz H, Eckl R, Busch G, Montens HP, Brandl R, Seidl S, Schomig A, Ott I. Membrane-type serine protease-1/matriptase induces interleukin-6 and-8 in endothelial cells by activation of protease-activated receptor-2: potential implications in atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:769-775. (Pubitemid 46606705)
12. Camerer E, Huang W, Coughlin SR. Tissue factor-and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA. 2000;97:5255-5260. (Pubitemid 30313705)
13. Nelken NA, Soifer SJ, O'Keefe J, Vu TK, Charo IF, Coughlin SR. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest. 1992;90:1614-1621.
14. Chieng-Yane P, Bocquet A, Letienne R, Bourbon T, Sablayrolles S, Perez M, Hatem SN, Lompre AM, Le Grand B, David-Dufilho M. Proteaseactivated receptor-1 antagonist F 16618 reduces arterial restenosis by down-regulation of tumor necrosis factor alpha and matrix metalloproteinase 7 expression, migration, and proliferation of vascular smooth muscle cells. J Pharmacol Exp Ther. 2010;336:643-651.
15. Marutsuka K, Hatakeyama K, Sato Y, Yamashita A, Sumiyoshi A, Asada Y. Protease-activated receptor 2 (PAR2) mediates vascular smooth muscle cell migration induced by tissue factor/factor VIIa complex. Thromb Res. 2002;107:271-276. (Pubitemid 35435387)
16. Cheung WM, D'Andrea MR, Andrade-Gordon P, Damiano BP. Altered vascular injury responses in mice deficient in protease-activated receptor-1. Arterioscler Thromb Vasc Biol. 1999;19:3014-3024. (Pubitemid 30029832)
17. Wilcox JN, Rodriguez J, Subramanian R, Ollerenshaw J, Zhong C, Hayzer DJ, Horaist C, Hanson SR, Lumsden A, Salam TA, et al. Characterization of thrombin receptor expression during vascular lesion formation. Circ Res. 1994;75:1029-1038. (Pubitemid 24351448)
18. Damiano BP, D'Andrea MR, de Garavilla L, Cheung WM, Andrade-Gordon P. Increased expression of protease activated receptor-2 (PAR-2) in balloon-injured rat carotid artery. Thromb Haemost. 1999;81:808-814. (Pubitemid 29216570)
19. Mirza H, Yatsula V, Bahou WF. The proteinase activated receptor-2 (PAR-2) mediates mitogenic responses in human vascular endothelial cells. J Clin Inv. 1996;97:1705-1714.
20. Kaneider NC, Leger AJ, Agarwal A, Nguyen N, Perides G, Derian C, Covic L, Kuliopulos A. 'Role reversal' for the receptor PAR1 in sepsisinduced vascular damage. Nat Immunol. 2007;8:1303-1312. (Pubitemid 350131169)
21. Tennant GM, Wadsworth RM, Kennedy S. PAR-2 mediates increased inflammatory cell adhesion and neointima formation following vascular injury in the mouse. Atherosclerosis. 2008;198:57-64. (Pubitemid 351406376)
22. Major CD, Santulli RJ, Derian CK, Andrade-Gordon P. Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice. Arterioscler Thromb Vasc Biol. 2003;23: 931-939. (Pubitemid 36713544)
23. Pawlinski R, Tencati M, Hampton CR, Shishido T, Bullard TA, Casey LM, Andrade-Gordon P, Kotzsch M, Spring D, Luther T, Abe J, Pohlman TH, Verrier ED, Blaxall BC, Mackman N. Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation. 2007; 116:2298-2306. (Pubitemid 350100336)
24. Schmidt VA, Nierman WC, Feldblyum TV, Maglott DR, Bahou WF. The human thrombin receptor and proteinase activated receptor-2 genes are tightly linked on chromosome 5q13. Br J Haematol. 1997;97:523-529. (Pubitemid 27261612)
25. Blackhart BD, Emilsson K, Nguyen D, Teng W, Martelli AJ, Nystedt S, Sundelin J, Scarborough RM. Ligand cross-reactivity within the proteaseactivated receptor family. J Biol Chem. 1996;271:16466-16471. (Pubitemid 26238996)
26. O'Brien PJ, Prevost N, Molino M, Hollinger MK, Woolkalis MJ, Woulfe DS, Brass LF. Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. J Biol Chem. 2000;275:13502-13509. (Pubitemid 30257415)
27. Covic L, Gresser AL, Talavera J, Swift S, Kuliopulos A. Activation and inhibition of G protein-coupled receptors by cell-penetrating membranetethered peptides. Proc Natl Acad Sci USA. 2002;99:643-648. (Pubitemid 34106565)
28. McEachron TA, Pawlinski R, Richards KL, Church FC, Mackman N. Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis. Blood. 2010;116:5037-5044.
29. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84:767-801. (Pubitemid 38823766)
30. Andrade-Gordon P, Derian CK, Maryanoff BE, Zhang H-C, Addo MF, Cheung W-M, Damiano BP, D'Andrea MR, Darrow AL, DeGaravilla L, Eckardt AJ, Giardino EC, Haertlein BJ, McComsey DF. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J Pharm Exp Therap. 2001;298:34-42. (Pubitemid 32574507)
31. Takada M, Tanaka H, Yamada T, Ito O, Kogushi M, Yanagimachi M, Kawamura T, Musha T, Yoshida F, Ito M, Kobayashi H, Yoshitake S, Saito I. Antibody to thrombin receptor inhibits neointimal smooth muscle cell accumulation without causing inhibition of platelet aggregation or altering hemostatic parameters after angioplasty in rat. Circ Res. 1998; 82:980-987. (Pubitemid 28225938)
32. Jacques SL, Kuliopulos A. Protease-activated receptor-4 uses dual prolines and an anionic recognition motif for thrombin recognition and cleavage. Biochem J. 2003;376:733-740. (Pubitemid 38058072)
33. Napoli C, Cicala C, Wallace JL, de Nigris F, Santagada V, Caliendo G, Franconi F, Ignarro LJ, Cirino G. Protease-activated receptor-2 modulates myocardial ischemia-reperfusion injury in the rat heart. Proc Natl Acad Sci USA. 2000;97:3678-3683. (Pubitemid 30183362)
34. Napoli C, De Nigris F, Cicala C, Wallace JL, Caliendo G, Condorelli M, Santagada V, Cirino G. Protease-activated receptor-2 activation improves efficiency of experimental ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2002;282:H2004-H2010. (Pubitemid 34663006)
35. Antoniak S, Rojas M, Spring D, Bullard T, Verrier E, Blaxall B, Mackman N, Pawlinski R. Protease-activated receptor 2 deficiency reduces cardiac ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol. 2010;30:2136-2142.
36. Vergnolle N, Hollenberg MD, Sharkey KA, Wallace JL. Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br J Pharmacol. 1999;127:1083-1090. (Pubitemid 29326629)
37. Vergnolle N, Bunnett NW, Sharkey KA, Brussee V, Compton SJ, Grady EF, Cirino G, Gerard N, Basbaum AI, Andrade-Gordon P, Hollenberg MD, Wallace JL. Proteinase-activated receptor-2 and hyperalgesia: a novel pain pathway. Nat Med. 2001;7:821-826. (Pubitemid 32691637)
38. Ferrell WR, Lockhart JC, Kelso EB, Dunning L, Plevin R, Meek SE, Smith AJ, Hunter GD, McLean JS, McGarry F, Ramage R, Jiang L, Kanke T, Kawagoe J. Essential role for proteinase-activated receptor-2 in arthritis. J Clin Invest. 2003;111:35-41. (Pubitemid 36134846)
39. Sevigny LM, Zhang P, Bohm A, Lazarides K, Perides G, Covic L, Kuliopulos A. Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins. Proc Natl Acad Sci USA. 2011; 108:8491-8496.
40. McCoy KL, Traynelis SF, Hepler JR. PAR1 and PAR2 couple to overlapping and distinct sets of G proteins and linked signaling pathways to differentially regulate cell physiology. Mol Pharmacol. 2010;77: 1005-1015.
41. Rzucidlo EM, Martin KA, Powell RJ. Regulation of vascular smooth muscle cell differentiation. J Vasc Surg. 2007;45(suppl A):A25-A32.
42. Liu X, Wu H, Byrne M, Krane S, Jaenisch R. Type III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development. Proc Natl Acad Sci USA. 1997;94:1852-1856. (Pubitemid 27113925)